The London start-up will use Series B funding and a European commercialisation deal with Ascensia Diabetes Care to scale manufacturing and prepare for regulatory trials of its less invasive continuous glucose monitor.
Sava Technologies is pushing a new approach to glucose monitoring with wearable microsensors designed to sit just beneath the skin and measure glucose continuously with less discomfort than conventional devices. The London-based company says the system is being developed for non-adjunctive use, meaning insulin dosing decisions could eventually be made without the routine confirmatory fingerstick checks still used in some settings. According to Sava, the underlying platform is also being built with room to measure other biomarkers in the future, which would broaden its use beyond diabetes care.
The company has now raised $36 million in Series B funding, with Ascensia Diabetes Care leading the round, and said the money will help it scale manufacturing ahead of a pivotal clinical study planned for 2026. Sava’s technology uses microsensors that are said to sit beneath the skin while causing less tissue disruption than traditional continuous glucose monitors. The company is targeting CE approval in Europe and says it is aiming for commercial launch within 18 to 24 months, although that timetable remains contingent on clinical and regulatory milestones.
Sava has also said it has already reported 10-day clinical evidence for its proprietary system, based on an independent study involving 46 people with type 1 diabetes and insulin-dependent type 2 diabetes. The company described the results as showing performance comparable with established continuous glucose monitors over the test period. If those findings are borne out in larger trials, they could strengthen the case for a device that combines continuous sensing with a less invasive user experience.
The partnership with Ascensia is central to the company’s go-to-market plan. Sava says Ascensia will initially handle European commercialisation, drawing on existing distribution channels and reimbursement relationships in diabetes care. For Ascensia, the deal adds a next-generation monitoring platform to a portfolio already focused on helping people manage diabetes, while for Sava it provides a route to market that could help move the technology from promising prototype to practical clinical tool.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
